Critical Comparison: GenVec (GNVC) and Pluristem Therapeutics (PSTI)

GenVec (NASDAQ: GNVC) and Pluristem Therapeutics (NASDAQ:PSTI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Insider & Institutional Ownership

6.2% of GenVec shares are held by institutional investors. Comparatively, 4.3% of Pluristem Therapeutics shares are held by institutional investors. 8.1% of GenVec shares are held by company insiders. Comparatively, 7.0% of Pluristem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares GenVec and Pluristem Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GenVec N/A N/A N/A ($3.67) -1.96
Pluristem Therapeutics $2.85 million 58.04 -$27.81 million ($0.32) -4.78

GenVec has higher earnings, but lower revenue than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than GenVec, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GenVec and Pluristem Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GenVec -3,748.25% -648.22% -271.77%
Pluristem Therapeutics N/A -100.14% -80.04%

Analyst Recommendations

This is a summary of current recommendations for GenVec and Pluristem Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GenVec 0 2 0 0 2.00
Pluristem Therapeutics 0 0 3 0 3.00

GenVec presently has a consensus price target of $7.00, indicating a potential downside of 2.64%. Pluristem Therapeutics has a consensus price target of $3.83, indicating a potential upside of 150.54%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Pluristem Therapeutics is more favorable than GenVec.

Summary

Pluristem Therapeutics beats GenVec on 8 of the 11 factors compared between the two stocks.

About GenVec

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

Receive News & Ratings for GenVec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply